1. Home
  2. ELUT vs GBIO Comparison

ELUT vs GBIO Comparison

Compare ELUT & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • GBIO
  • Stock Information
  • Founded
  • ELUT 2015
  • GBIO 2016
  • Country
  • ELUT United States
  • GBIO United States
  • Employees
  • ELUT N/A
  • GBIO N/A
  • Industry
  • ELUT Medical Specialities
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELUT Health Care
  • GBIO Health Care
  • Exchange
  • ELUT Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • ELUT 38.2M
  • GBIO 41.2M
  • IPO Year
  • ELUT 2020
  • GBIO 2020
  • Fundamental
  • Price
  • ELUT $0.66
  • GBIO $5.27
  • Analyst Decision
  • ELUT Strong Buy
  • GBIO Buy
  • Analyst Count
  • ELUT 2
  • GBIO 4
  • Target Price
  • ELUT $7.00
  • GBIO $10.67
  • AVG Volume (30 Days)
  • ELUT 224.2K
  • GBIO 82.2K
  • Earning Date
  • ELUT 11-06-2025
  • GBIO 11-05-2025
  • Dividend Yield
  • ELUT N/A
  • GBIO N/A
  • EPS Growth
  • ELUT N/A
  • GBIO N/A
  • EPS
  • ELUT N/A
  • GBIO N/A
  • Revenue
  • ELUT $21,746,000.00
  • GBIO $15,270,000.00
  • Revenue This Year
  • ELUT $1.90
  • GBIO N/A
  • Revenue Next Year
  • ELUT $6.37
  • GBIO N/A
  • P/E Ratio
  • ELUT N/A
  • GBIO N/A
  • Revenue Growth
  • ELUT 24.08
  • GBIO N/A
  • 52 Week Low
  • ELUT $0.66
  • GBIO $3.00
  • 52 Week High
  • ELUT $5.12
  • GBIO $16.79
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 18.44
  • GBIO 40.89
  • Support Level
  • ELUT $0.69
  • GBIO $5.30
  • Resistance Level
  • ELUT $0.77
  • GBIO $5.89
  • Average True Range (ATR)
  • ELUT 0.06
  • GBIO 0.28
  • MACD
  • ELUT -0.01
  • GBIO -0.01
  • Stochastic Oscillator
  • ELUT 0.09
  • GBIO 34.38

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: